Influenza Virosomes as Delivery Systems for Antigens

Delivery Technologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids and Vaccines

Volumn , Issue , 2009, Pages 377-393

  Amacker, Mario ^a   Moese, Stefan ^b   Kammer, Andreas R ^a   Helenius, Ari ^c   Zurbriggen, Rinaldo ^a  

^a Pevion Biotech Ltd   (Switzerland)

^b 3 V Biosciences ^*  (Switzerland)

^c ETH ZURICH   (Switzerland)

Author keywords

Antigen virosome drug delivery system; Immune stimulating reconstituted influenza virosomes (IRIVs); Immunization experiments in C57Bl 6 and Balb c (Charles River); Influenza virosomes enhancing immune response against co delivered antigens; Influenza virosomes as delivery systems for antigens; Photon correlation spectroscopy (PCS); Virosomal formulation; Virosome uptake into HeLa cells; Viruses binding first to cell surface

Indexed keywords

EID: 79955076538     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470688397.ch19     Document Type: Chapter

References (60)

1. Fodor, E. and Brownlee, G.G. (2002) Influenza virus replication, in Influenza (ed. C.W. Potter), Elsevier, Amsterdam, The Netherlands, pp. 1-29.
2. Lamb, R.A. and Krug, R.M. (2001) Orthomyxoviridae: the viruses and their replication, in Fields Virology (eds D.M. Knipe and P.M. Howley), Lippincott Williams & Wilkins, Philadelphia, pp. 1487-1531.
3. Gluck, R. and Metcalfe, I.C. (2003) Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems. Vaccine, 21, 611-615.
4. Huckriede, A., Bungener, L., Stegmann, T. et al. (2005) The virosome concept for influenza vaccines. Vaccine, 23 (Suppl. 1), S26-S38.
5. Moser, C., Metcalfe, I.C. and Viret, J.F. (2003) Virosomal adjuvanted antigen delivery systems. Expert. Rev. Vaccines, 2, 189-196.
6. Zurbriggen, R. (2003) Immunostimulating reconstituted influenza virosomes. Vaccine, 21, 921-924.
7. Moser, C., Amacker, M., Kammer, A.R. et al. (2007) Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert. Rev. Vaccines., 6, 711-721.
8. Amacker, M., Engler, O., Kammer, A.R. et al. (2005) Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Int. Immunol., 17, 695-704.
9. Kammer, A.R., Amacker, M., Rasi, S. et al. (2007) A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses. Vaccine, 25, 7065-7074.
10. Cusi, M.G., Terrosi, C., Savellini, G.G. et al. (2004) Efficient delivery of DNA to dendritic cells mediated by influenza virosomes. Vaccine, 22, 735-739.
11. Felnerova, D., Viret, J.F., Gluck, R. and Moser, C. (2004) Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr. Opin. Biotechnol., 15, 518-529.
12. Liu, X., Siegrist, S., Amacker, M. et al. (2006) Enhancement of the immunogenicity of synthetic carbohydrates by conjugation to virosomes: a leishmaniasis vaccine candidate. ACS Chem. Biol., 1, 161-164.
13. Schumacher, R., Amacker, M., Neuhaus, D. et al. (2005) Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/ MART-1(26-35) peptide encapsulated into virosomes in vitro. Vaccine, 23, 5572-5582.
14. Waelti, E.R. and Gluck, R. (1998) Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes). Int. J. Cancer, 77, 728-733.
15. Westerfeld, N. and Zurbriggen, R. (2005) Peptides delivered by immunostimulating reconstituted influenza virosomes. J. Pept. Sci., 11, 707-712.
16. Zurbriggen, R., Amacker, M., Kammer, A.R. et al. (2005) Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer ' s disease. J. Mol. Neurosci., 27, 157-166.
17. Okitsu, S.L., Mueller, M.S., Amacker, M. et al. (2008) Preclinical profiling of the immunogenicity of a two-component subunit malaria vaccine candidate based on virosome technology. Hum. Vaccin., 4, 106-114.
18. Genton, B., Pluschke, G., Degen, L. et al. (2007) A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. PLoS ONE, 2, e1018.
19. Okitsu, S.L., Silvie, O., Westerfeld, N. et al. (2007) A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial. PLoS ONE, 2, e1278.
20. Okitsu, S.L., Boato, F., Mueller, M.S. et al. (2007) Antibodies elicited by a virosomally formulated Plasmodium falciparum serine repeat antigen-5 derived peptide detect the processed 47 kDa fragment both in sporozoites and merozoites. Peptides, 28, 2051-2060.
21. Okitsu, S.L., Kienzl, U., Moehle, K. et al. (2007) Structure-activity-based design of a synthetic malaria peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation. Chem. Biol., 14, 577-587.
22. Thompson, F.M., Porter, D.W., Okitsu, S.L. et al. (2008) Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS ONE, 3, e1493.
23. Correale, P., Vecchio, D., Renieri, M.T. et al. (2008) Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccine. Cancer Lett., 263, 291-301.
24. Gluck, R. (1997) Influenza immunization. Biologicals, 25, 221-225.
25. Loutan, L., Bovier, P., Althaus, B. and Gluck, R. (1994) Inactivated virosome hepatitis A vaccine. Lancet, 343, 322-324.
26. Zurbriggen, R. and Gluck, R. (1999) Immunogenicity of IRIV-versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice. Vaccine, 17, 1301-1305.
27. Zurbriggen, R., Novak-Hofer, I., Seelig, A. and Gluck, R. (2000) IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization. Prog. Lipid. Res., 39, 3-18.
28. Adamina, M., Guller, U., Bracci, L. et al. (2006) Clinical applications of virosomes in cancer immunotherapy. Expert Opin. Biol. Ther., 6, 1113-1121.
29. Adamina, M., Schumacher, R., Zajac, P. et al. (2006) Advanced liposomal vectors as cancer vaccines in melanoma immunotherapy. J. Liposome Res., 16, 195-204.
30. Angel, J., Chaperot, L., Molens, J.P. et al. (2007) Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells. Vaccine, 25, 3913-3921.
31. Bungener, L., Serre, K., Bijl, L. et al. (2002) Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine, 20, 2287-2295.
32. Schumacher, R., Adamina, M., Zurbriggen, R. et al. (2004) Influenza virosomes enhance class I restricted CTL induction Through CD4+ T cell activation. Vaccine, 22, 714-723.
33. Bungener, L., Huckriede, A., de Mare, A. et al. (2005) Virosome-mediated delivery of protein antigens in vivo : efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine, 23, 1232-1241.
34. Huckriede, A., Bungener, L., ter Veer, W. et al. (2003) Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity. Vaccine, 21, 925-931.
35. Grgacic, E.V. and Anderson, D.A. (2006) Virus-like particles: passport to immune recognition. Methods, 40, 60-65.
36. Bachmann, M.F., Kalinke, U., Althage, A. et al. (1997) The role of antibody concentration and avidity in antiviral protection. Science, 276, 2024-2027.
37. Justewicz, D.M., Doherty, P.C. and Webster, R.G. (1995) The B-cell response in lymphoid tissue of mice immunized with various antigenic forms of the influenza virus hemagglutinin. J. Virol., 69, 5414-5421.
38. Pfeiffer, B., Peduzzi, E., Moehle, K. et al. (2003) A virosome-mimotope approach to synthetic vaccine design and optimization: synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate. Angew. Chem. Int. Ed., 42, 2368-2371.
39. Bovier, P.A., Bock, J., Loutan, L. et al. (2002) Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J. Med. Virol., 68, 489-493.
40. Clarke, P.D., Adams, P., Ibanez, R. and Herzog, C. (2006) Rate, intensity, and duration of local reactions to a virosome-adjuvanted vs. an aluminium-adsorbed hepatitis A vaccine in UK travellers. Travel Med. Infect. Dis., 4, 313-318.
41. D'Acremont, V., Herzog, C. and Genton, B. (2006) Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. J. Travel Med., 13, 78-83.
42. Holzer, B.R., Hatz, C., Schmidt-Sissolak, D. et al. (1996) Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine, 14, 982-986.
43. Gaeta, G.B., Stornaiuolo, G., Precone, D.F. et al. (2002) Immunogenicity and safety of an adjuvanted influenza vaccine in patients with decompensated cirrhosis. Vaccine, 20 (Suppl. 5), B33-B35.
44. Kanra, G., Marchisio, P., Feiterna-Sperling, C. et al. (2004) Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr. Infect. Dis. J., 23, 300-306.
45. Schaad, U.B., Buhlmann, U., Burger, R. et al. (2000) Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis. Antimicrob. Agents Chemother., 44, 1163-1167.
46. Marsh, M. and Helenius, A. (1989) Virus entry into animal cells. Adv. Virus Res., 36, 107-151.
47. Rust, M.J., Lakadamyali, M., Zhang, F. and Zhuang, X. (2004) Assembly of endocytic machinery around individual influenza viruses during viral entry. Nat. Struct. Mol. Biol., 11, 567-573.
48. Schijns, V.E. (2000) Immunological concepts of vaccine adjuvant activity. Curr. Opin. Immunol., 12, 456-463.
49. Correale, P., Cusi, M.G., Sabatino, M. et al. (2001) Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes. Eur. J. Cancer, 37, 2097-2103.
50. Cusi, M.G. and Gluck, R. (2000) Potential of DNA vaccines delivered by influenza virosomes. Vaccine, 18, 1435.
51. Daemen, T., de Mare, A., Bungener, L. et al. (2005) Virosomes for antigen and DNA delivery. Adv. Drug Deliv. Rev., 57, 451-463.
52. de Jonge, J., Holtrop, M., Wilschut, J. and Huckriede, A. (2006) Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs. Gene Ther., 13, 400-411.
53. Schoen, P., Bron, J. and Wilschut, J. (1993) Delivery of foreign substances to cells mediated by fusion-active reconstituted influenza virus envelopes (virosomes). J. Liposome Res., 3, 767-792.
54. Schoen, P., Chonn, A., Cullis, P.R. et al. (1999) Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles. Gene Ther., 6, 823-832.
55. Tuffin, G., Waelti, E., Huwyler, J. et al. (2005) Immunoliposome targeting to mesangial cells: a promising strategy for specific drug delivery to the kidney. J. Am. Soc. Nephrol., 16, 3295-3305.
56. Waelti, E., Wegmann, N., Schwaninger, R. et al. (2002) Targeting her-2/neu with antirat Neu virosomes for cancer therapy. Cancer Res, 62, 437-444.
57. Weis, W., Brown, J.H., Cusack, S. et al. (1988) Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature, 333, 426-431.
58. Matlin, K.S., Reggio, H., Helenius, A. and Simons, K. (1982) The entry of enveloped viruses into an epithelial cell line. Prog. Clin. Biol. Res., 91, 599-611.
59. Sternberg, B. (1993) Freeze-fracture electron microscopy of liposomes, in Liposome Technology, vol. 1 (ed. G. Gregoriadis), CRC Press, London, pp. 363-383.
60. Sternberg, B. (1996) Liposomes as a model for membrane structures and structural transformations: a liposome album, in Handbook of Nonmedical Applications of Liposomes, vol. IV (eds D.D. Lasic and Y. Barenholz), CRC Press, London, pp. 271-297.